A team of researchers from the Institute of Biomedical Sciences has checked the effectiveness of Bevacizumab used against eye cancer, for the treatment of uveitis, which prevents the spread of inflammation.
Uveitis - inflammation uvei - eye tissue between the sclera and the retina. This can be caused by infections or autoimmune diseases. Uvea provides most of the blood supply to the retina, so early treatment of inflammation may be a key to preventing the effects in other ocular tissues - if the state does not pass in due time, the inflammation can spread to the vitreous and retina. Researchers at the Institute of Biomedical Sciences of the University Cardenal Herrera University CEU (UCH CEU) in Valencia tested the efficacy of bevacizumab in the treatment of uveitis, using an experimental model. The results, which provide a new strategy for the treatment of uveitis, and prevent its consequences, published in «Frontiers in Pharmacology».
Professor Francisco Bosch, Director of the Institute of Biomedical Sciences TSEKH CEU, says, "Bevacizumab - a medicine used in combination immunotherapy for treatment of tumors, which also has a number of ophthalmic applications for treating eye diseases such as diabetic retinopathy, macular edema or glaucoma." The research team, led by Dr. Bosch, studied the anti-inflammatory ability of the drug and its potential risks with regard to the toxicity induced uveitis in an experimental model.
Professor Bosch says: "The results of the cell count and histopathology obtained by our team, confirmed the possibility of medicine to prevent inflammation uvei not only, but also of the retina and vitreous chamber, as well as to rule out the risk of retinal degradation, which may be associated with the use of drugs."
These results also provide appropriate data arguments associated with the use of injectable drugs with anti-aging vascular endothelial factor, anti-VEGF. "Despite the fact that bevacizumab, commercialized like Avastin, was originally developed to treat several types of cancer, it is generally used in ophthalmology, despite the fact that this use is not recommended. Our results suggest that in this area it is as safe and effective as Lucentis is, which has been developed specifically for ophthalmic purposes, but it is more expensive ", - says Dr. Bosch.